Drug Resistance Assay

• The high take rate of subrenal capsule xenografts enables researchers to readily study tumor behavior (growth/progression/metastasis/acquired drug resistance) of a great variety of precancerous and cancerous diseases in vivo.

• Many of our tumor tissue lines have known drug sensitivity/resistance for various cytotoxic drugs acquired from previous studies.

• Status of drug-resistance markers in our tumor lines is known, or can be readily screened using tissue microarray or mRNA expression profiles.

• Acquired drug resistance can also be established by treating tumor lines with multiple cycles and selecting drug-resistant subpopulations.

• Lung cancer and ovarian cancer tumor lines show a variety of responses to standard chemotherapy.

 

Figure 1. Drug responses in ovarian Living Tumor Lines


T/C = average treated tumor mass/average control tumor mass

Figure 2. Drug responses in lung Living Tumor Lines

T/C = average treated tumor mass/average control tumor mass
CDDP-cisplatin
VNB-vinorelbine
TXT-docetaxel

• Drug resistance lines are being developed via multiple cycles of standard chemotherapy treatment of selected Living Tumor lines

Subline origin Sublines Bio-characteristics of sublines
LTL-79 LTL-79/C13 10 cycles of CDDP+VP16 treatment. Tumor is resistant to the drug
LTL-117 LTL-117/C6 6 cycles of CDDCP+VNB. Tumor is still response to the drug.
LTL-175 LTL-175/C6 6 cycles of carboplatin and paclitaxol treatment. Tumor is still response to the drug.
LTL-297B LTL-297B/C4 4 cycles of carboplatin and paclitaxol treatment. Tumor is resistant to the drug.